Observational studyJournal of neurology2019

Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.

Carmen Alcalá et al.PubMed ↗Publisher ↗

No numbers read from the abstract.